Business

Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as

articleSana Biotechnology, Inc.June 2, 20213/company/sana-biotechnology-inc/news/sana-biotechnology-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

About this update from Sana Biotechnology, Inc.

[{"type":"text","content":"SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on Wednesday, June 9, 2021. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website at www.Sana.com. A replay of the presentation will be available at the same location for 30 days following the conference. About Sana BiotechnologySana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 280 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco. For more information about Sana Biotechnology, please visit https://sana.com/. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical and clinical and regulatory development plans and timing expectations; Sana’s participation in the Goldman Sachs 42nd Annual Global Healthcare Conference; and the subject matter of Sana’s presentation at that conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned...

More updates from Sana Biotechnology, Inc.